AZN · story · 9 November – 10 November
AstraZeneca · 3 headlines from 3 outlets, from 9 November 2026 to 10 November 2026.
Coverage describes AstraZeneca's biomarker testing and body-check cancer awareness campaign.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
LBB - Little Black Book is the largest at 3.3, ahead of MyChesCo (3.3). Oncodaily is the smallest at 2.5.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| LBB - Little Black Book | 3.3 |
| MyChesCo | 3.3 |
| Oncodaily | 2.5 |
| Outlet | Headlines | Average tone |
|---|---|---|
| LBB - Little Black Book | 1 | +3.3 |
| MyChesCo | 1 | +3.3 |
| Oncodaily | 1 | +2.5 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +3.3 | Its cancer awareness campaign won creative recognition. |
| +2.5 | Awareness campaign supporting its oncology testing, minor positive. |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +3.3 | Awareness campaign aimed at improving cancer testing uptake. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.